The purpose of the study is to better understand the experience of loved ones whose family members were treated for violence injuries at MUSC, and what services could potentially be improved. This study will involve administering surveys to loved ones of patients who are treated for injuries due to intentional violence at MUSC. They will be recruited via flyers and information sheets. Survey questions will address perceptions of their loved ones healthcare experience, interactions with staff members, impact of the Turning the Tide Violence Intervention Program (TTVIP), what perceived needs they have, and what services have been provided. Responses of those that have loved ones who enrolled in TTVIP compared to those who did not will be compared to assess for differences.

OBSERVE-ARDS is a prospective, multi-center, observational human subjects research study designed to collect longitudinal clinical data and remnant biological specimens from adults with clinically defined ARDS. The study is non-interventional and does not introduce, modify, or recommend any diagnostic, therapeutic, or management decisions. All participant care is determined solely by the treating clinical teams in accordance with routine clinical practice and dictated by any other clinical studies in which they are enrolled. The study is conducted to support efforts to improve understanding of biological heterogeneity in ARDS and to enable the development and evaluation of biomarker-driven endotyping and treatment-prediction algorithms.

This is a phase 2, randomized, multiple-dose, placebo-controlled, multicenter study to assess the safety, efficacy, and PK of CSL889 IV administration in adults and adolescents with SCD presenting with VOC. All subjects will receive a once daily dose of CSL889 or placebo until VOC resolution or Day 5, whichever comes first.

This is a Phase 2 platform research study that is assessing three different investigational medications (versus placebo) for hospitalized adults who have Acute Respiratory Distress Syndrome (ARDS). As a platform study, each of the three treatment groups will receive a different investigational drug (or placebo) depending on the severity of their ARDS. Participants will also receive standard treatment as determined by the treating physician.

The purpose of the study is to assess services, experiences, needs and outcomes for patients that experience violent injuries in the year after injury, and to assess differences among those that are served by the Turning the Tide Violence Intervention Program (TTVIP) compared to those who are not. This will be done through a series of four 25-35 minute surveys that will be administered over the course of a year. Participants will be asked questions about their physical and mental health, violence exposures and risk, healthcare experience, ongoing needs, services provided by the TTVIP and overall recovery. This information will be used to better understand the experiences of patients that experience a violent injury, how HVIPs impact their outcomes, and how healthcare teams and hospital violence intervention programs (HVIPs) can be improved within trauma centers.

This is a double blind randomized controlled trial designed to test the effects of intravenous acetaminophen (IV-A) and/or intravenous ketorolac (IV-K) at reducing pain in children with acute respiratory failure (ARF) on invasive mechanical ventilation (MV). Consented participants will be randomized in equal proportions to receive IV-A, IV-K, both, or neither.

The purpose of the study is to assess healthcare interactions and violence intervention services provided to patients and their loved ones that are treated for firearm injuries. This will be done in a 30 to 45-minute interview where participants will be asked questions about their healthcare experience, services provided by the Turning the Tide Violence Intervention Program (TTVIP), what went well with their care and services, and what could be improved. This information will be used to better understand the experiences and needs of patients and families that experience a violent injury, what is done well by trauma centers and hospital violence intervention programs (HVIPs), and what could be improved in their experience and recovery.

ICUconnect is a innovative mobile app-based primary palliative care intervention. This is a multicenter randomized controlled trial to test the intervention's efficacy in a population diverse in race, ethnicity, and geography that reflects the real-world experience of patients and family members.

ICUconnect is a innovative mobile app-based primary palliative care intervention. This is a multicenter randomized controlled trial to test the intervention's efficacy in a population diverse in race, ethnicity, and geography that reflects the real-world experience of patients and family members.

This study is a multicenter, randomized, double-blinded, placebo-controlled trial to evaluate the safety and efficacy of ExoFlo for the treatment of moderate-to-severe ARDS (Acute Respiratory Distress Syndrome). The purpose of this study is to research and evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles, ExoFlo, as treatment for Moderate-to-Severe ARDS. Bone Marrow Mesenchymal Stem Cell (bmMSC)-Derived Extracellular Vesicles is an investigational drug created from human bone marrow being studied for the treatment of moderate-to-severe ARDS. This is a research study that will involve monitoring oxygen and inflammation levels after taking the investigational product and assessing the safety of the investigational product. The experimental treatment is a biologic product called Bone Marrow Mesenchymal Stem Cell (bmMSC)-Derived Extracellular Vesicles Allograft Product ExoFlo, which is purified from the bone marrow of a healthy well-screened individual. Participants will receive either 15mL of the investigational product with 85 mL of normal saline or 100 mL of normal saline only (placebo). The expected duration of participation in the study is a maximum of 61 days, which includes 1-day screening prior to treatment and 60 days following the first treatment.